Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
VKViking Therapeutics, Inc. logo

Viking Therapeutics, Inc. (VKTX)

NASDAQ Capital Market · Currency in USD
$24.40 ▼ -1.43 (-5.54%)
At close: Oct 23, 4:00 PM ET. Market closed.
$24.45 ▲ +0.05 (+0.19%)
After hours: Oct 23, 7:59 PM ET

Summary

Previous Close
$25.83
Open
$25.54
Day's Range
$24.36 – $25.74
52 Week Range
$24.36 – $43.15
Volume
4,655,566
Avg. Volume
4,092,104
Market Cap
$3.10B
Beta (5Y Monthly)
0.65
PE Ratio (TTM)
--
EPS (TTM)
-$4.61
Earnings Date
Oct 28, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$97.80

Profile: Viking Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
65
CEO
Brian Lian

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD).

Earnings

Next report: Wed, Oct 28, 2026
EPS estimate -$1.06
DateEst.Actual
Jul 29, 2026-$1.23-$1.10Beat
Apr 29, 2026-$1.01-$1.37Miss
Feb 11, 2026-$0.89-$1.38Miss
Oct 22, 2025-$0.70-$0.81Miss
Jul 23, 2025-$0.44-$0.58Miss
Apr 23, 2025-$0.34-$0.41Miss

Analyst view

Consensus price target
$97.80 ▲ +300.8%
Range $85.00 – $120.00
Rating: Buy
Buy 96% · Hold 4% · Sell -0%

Get free alerts on VKTX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.